Schistosoma mansoni SmKI-1 serine protease inhibitor binds to elastase and impairs neutrophil function and inflammation
Fig 4
SmKI-1 reduces hepatic APAP-induced injury.
(a) MPO and (b) Elastase activities were measured in rSmKI-1 treated mice during liver APAP-induced hepatotoxicity. Treated-mice received SmKI-1 (10 mg/kg) or PBS vehicle i.v. 15 min prior APAP administration (600 mg/kg). (c) Number of neutrophils per field of view (FOV) in the liver of rSmKI-1 treated animals. (d) Liver confocal intravital microscopy showing neutrophil (anti-GR1 PE in red) migration into necrotic sites (Sytox green staining) following 24 hours of APAP challenge. Scale bar = 100 μm. (e) Left panels represent histology of hematoxylin and eosin-stained liver sections, scale bar = 300μm. In right panels, liver damage is highlighted. (f) serum ALT levels confirmed severe liver damage in APAP group and reduction of liver necrosis in mice treated with APAP+SmKI-1. Results are the mean ± SEM of n = 6 per group. An asterisk indicate statistically significant differences of rSmKI-1 compared to APAP group (p< 0.05) or ** p< 0.005.